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The NS1 protein of the influenza A/Udorn/72 virus possesses two important functional domains: an RNA-binding domain
near the amino-terminal end and an effector domain in the carboxyl half of the molecule. Though the NS1 proteins of
influenza A and B viruses share little sequence homology, an RNA-binding domain with the same activities is preserved in
the NS1 protein of influenza B/Lee/40 virus. The RNA-binding domains of the NS1 proteins of these influenza A and B
viruses share the following properties: (i) they specifically bind to the same three RNA targets, poly(A), U6 snRNA, and
double-stranded (ds) RNA; (ii) a polypeptide containing an amino-terminal sequence of the protein possesses all the RNA-
binding activity of the full-length protein and exists in the form of a dimer; (iii) the binding to U6 snRNA causes an inhibition
of pre-mRNA splicing in vitro; and (iv) the binding to dsRNA blocks the activation of the PKR kinase in vitro. The conservation
of the RNA-binding domain of the NS1 protein among influenza A and B viruses strongly suggests that this domain is
required for the replication of all these influenza viruses. In contrast, the NS1 protein of influenza B virus (NS1B protein)
lacks an effector domain that functions like that of the NS1 protein of influenza A virus (NS1A protein). The effector domain
of the NS1A protein is required for two of its in vivo activities: the inhibition of the nuclear export of poly(A)-containing
mRNA and the inhibition of pre-mRNA splicing. The NS1B protein lacks these two in vivo activities. In addition, a naturally
occuring, truncated NS1A protein lacks such an effector domain. Consequently, an effector domain that functions like that
of full-length NS1A proteins is not absolutely required for the replication of influenza A and B viruses. We discuss the
implications of these results for the roles of the RNA-binding and effector domains of the NS1 protein during infection by
influenza A and B viruses. q 1996 Academic Press, Inc.
INTRODUCTION and NA (neuraminidase) genes. Segment 7 of both influ-
enza A and B viruses encode two proteins, but two differ-
Influenza viruses have been classified into types A, B,
ent posttranscriptional mechanisms are employed to ex-
and C based on the immunological relatedness of their
press the two proteins. With influenza A viruses, the co-
nucleocapsid (NP) proteins (Kilbourne, 1975). Thus, the
linear transcript of the M genome segment, the M1
influenza A virus NP protein is immunologically unrelated
mRNA, encodes the M1 (matrix) protein, and the M2
to the NP proteins of influenza B and C viruses. Of the
mRNA that encodes the M2 (ion channel) protein is pro-
three types, influenza A viruses have been the most inten-
duced by splicing of M1 mRNA in the nucleus (Lamb and
sively studied, but not all of the properties of A viruses
Choppin, 1981). This splicing is controlled by both theare shared by the B and C influenza viruses (reviewed
complex of the three viral polymerase proteins and thein Lamb, 1989).
cellular SF2/ASF splicing factor (Shih et al., 1995; ShihThe genomes of influenza A and B viruses are similar
and Krug, 1996). In contrast, with influenza B viruses, thein that both are composed of eight segments of single-
colinear transcript of the M segment, the M1 mRNA, isstranded RNA of negative polarity, and most of the pro-
not spliced, but rather is translated as a bicistronic mRNAteins encoded by the corresponding genome segments
in the cytoplasm into two proteins, M1 (matrix) and aserve similar functions (Lamb, 1983). However, the sizes
protein called BM2 (Horvath et al., 1990). However, theof both the genome segments and their encoded proteins
BM2 protein of influenza B virus has no homology withdiffer between the A and B viruses (reviewed in Lamb,
the influenza A virus M2 ion channel protein. The pre-1989). In addition, fundamental differences in the mecha-
sumed B virus counterpart to the A virus M2 protein isnisms of expression of several of the viral genes have
the NB protein, which is encoded by the genome seg-been documented, specifically involving the M (matrix)
ment that also encodes the NA protein (Williams and
Lamb, 1986). The transcript of the B virus NA segment,
1 To whom correspondence and reprint requests should be ad-
NA mRNA, is a bicistronic mRNA (Shaw et al., 1983),dressed at Department of Molecular Biology and Biochemistry, Rutgers
whereas the influenza A virus NA mRNA is monocistronicUniversity, CABM, Room 305, 679 Hoes Lane, Piscataway, NJ 08855.
Fax: (908) 235-4880. E-mail: krug@mbcl.rutgers.edu. and is translated into only the NA protein (Colman and
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Ward, 1985). Fundamental differences in the biological an RNA-binding protein and in fact binds to the same
three RNA targets as the NS1A protein. The binding ofproperties of influenza A and B viruses have also been
found. For example, influenza B virus, but not A virus, this protein to U6 snRNA and dsRNA results in the inhibi-
tion of pre-mRNA splicing in vitro and in the blocking ofinfections in humans are associated with the develop-
ment of Reye’s syndrome (Douglas, 1975). the activation of the PKR kinase, respectively, as pre-
viously documented for the NS1A protein (Lu et al., 1994,Both influenza A and B viruses encode a protein called
NS1 (nonstructural protein 1) that is the translation prod- 1995; Qiu et al., 1995). However, the NS1 protein of influ-
enza B virus lacks two of the in vivo activities exhibiteduct of the colinear transcript (NS1 mRNA) of the smallest
genome RNA segment (Lamb and Lai, 1980; Briedis et by the NS1 protein of influenza A virus. Thus, neither the
inhibition of the nuclear export of mRNA nor the inhibitional., 1981). The NS1 proteins of the A and B viruses share
very little sequence homology, and the NS1B proteins of pre-mRNA splicing occurs in cells transfected with the
NS1B gene. This strongly suggests that the NS1B proteinare usually larger than the NS1A proteins (Briedis and
Lamb, 1982). For example, the NS1 protein encoded by lacks an effector domain that functions like that of the
NS1 protein of most influenza A virus strains. There isB/Lee/40 virus is 281 amino acids long, whereas the NS1
protein encoded by A/Udorn/72 is only 237 amino acids one influenza A virus strain, however, which encodes a
NS1 protein that lacks the carboxyl region including thelong.
It is not known whether the NS1 proteins of the influ- effector domain (Norton et al., 1987), and we show that
such a naturally occurring truncated NS1A protein be-enza A and B viruses perform similar functions during
infection. Several functions of the NS1 protein of influ- haves similarly to the full-length NS1B protein in all of
our in vitro and in vivo functional assays.enza A virus have recently been elucidated (Alonso-
Caplen et al., 1992; Fortes et al., 1994; Lu et al., 1994,
1995; Qian et al., 1994; Qiu and Krug, 1994; Qiu et al.,
MATERIALS AND METHODS
1995). The NS1A protein of A/Udorn/72 virus contains
two functional domains, an RNA-binding domain near the Plasmid construction and protein purification
amino terminal end and an effector domain in the car-
boxyl half of the molecule (Qian et al., 1994). The NS1A All the NS1 genes described in this paper contain a
3* splice site mutation to eliminate the production of NS2protein has been shown to function in several posttran-
scriptional steps. First, this protein binds to the poly(A) mRNA (Lamb, 1989). The NS1 gene of influenza A/Udorn/
72 virus has been described previously (Alonso-Caplenof mRNA (Qiu and Krug, 1994) and inhibits the nuclear
export of poly(A)-containing mRNAs (Alonso-Caplen et et al., 1992; Qiu and Krug, 1994). The NS1 gene of influ-
enza B/Lee/40 virus in the pBR322 plasmid was providedal., 1992; Fortes et al., 1994; Qian et al., 1994; Qiu and
Krug, 1994). In addition, the NS1A protein binds to a by Robert A. Lamb (Briedis and Lamb, 1982). PCR was
used to introduce HindIII and SmaI sites at the 5* andstem-bulge in a key spliceosomal RNA, U6 small nuclear
RNA (snRNA) (Qiu et al., 1995), and inhibits pre-mRNA 3* ends, respectively, of the DNA sequence encoding the
NS1B protein. This NS1B sequence was cloned into thesplicing both in vivo (Fortes et al., 1994; Lu et al., 1994)
and in vitro (Lu et al., 1994; Qiu et al., 1995). Only the HindIII and SmaI sites of the pBC12 plasmid, and the
resulting plasmid was used for transfections. The sameRNA-binding domain is needed to inhibit splicing in vitro,
but both the RNA-binding and effector domains are re- NS1B sequence was blunt-ended and ligated into the
unique SmaI site of the pGEX-3X (Phamacia) expressionquired for the inhibition of poly(A)-containing mRNA nu-
clear export and of pre-mRNA splicing in vivo (Lu et al., vector. The resulting vector was transformed into Esche-
richia coli JM101 to express the GST–NS1B fusion pro-1994; Qian et al., 1994). Finally, the NS1A protein binds
to double-stranded RNA (dsRNA) in a sequence-indepen- tein. To prepare GST fusion proteins containing the 68,
78, 93, or 103 amino-terminal amino acids of the NS1Bdent manner (Hatada and Futada, 1992; Lu et al., 1995),
thereby blocking the dsRNA-mediated activation of the protein, two stop codons (TAGTAA) were introduced into
the appropriate positions of the NS1B reading frame us-cellular PKR kinase in vitro (Lu et al., 1995). If activated,
the PKR kinase phosphorylates the a subunit of the trans- ing PCR. The NS1 gene of influenza A/Turkey/Oregon/
71 virus in a pBR322 plasmid was provided by Peterlation initiation factor eIF2, causing an inhibition of cellu-
lar and viral protein synthesis (reviewed in Rhoads, 1993; Palese (Norton et al., 1987). The appropriate 10 nucleo-
tides were inserted into this NS1 gene using PCR toSamuel, 1993). Only the RNA-binding domain of the NS1A
protein is needed for blocking PKR kinase activation in generate the NS1 gene of influenza A/Duck/Alberta/60/
76 virus (Norton et al., 1987). The GST fusion proteinsvitro (Lu et al., 1995).
The present study demonstrates that the NS1 protein were purified and, where indicated, were cleaved using
factor Xa as described previously (Qiu and Krug, 1994).of influenza B virus shares some, but not all, of the prop-
erties of the NS1 protein of influenza A virus. Like its A The purity of all proteins were established by gel electro-
phoresis followed by Coomassie blue staining.virus counterpart, the NS1 protein of influenza B virus is
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RNA-binding assays In vitro splicing assays
To prepare a splicing precursor, a b-globin minigeneThe following 32P-labeled RNA targets were prepared
in pGEM1 linearized by BamHI was transcribed in theas previously described: U6 snRNA (Qiu et al., 1995);
presence of [a-32P]GTP by SP6 RNA polymerase, as de-pGEM1 dsRNA (Lu et al., 1995); poly(A) (Qiu and Krug,
scribed previously (Agris et al., 1989). Splicing reactions,1994). The RNA-binding assays were carried out as de-
in a final volume of 25 ml, were carried out with 10 ml ofscribed previously (Qiu and Krug, 1994; Lu et al., 1995).
HeLa cell nuclear extract essentially as described pre-Briefly, the indicated amounts of protein and target RNA
viously (Nemeroff et al., 1992; Lu et al., 1994). The splicingwere incubated on ice for 30 min in 20-ml binding reac-
reactions were incubated at 307 for 2 hr. RNA was ex-tions containing 43 mM Tris–HCl, pH 8.0, 50 mM KCl,
tracted and analyzed by electrophoresis on a 5% denatur-8% glycerol, 2.5 mM dithiothreitol, 50 mg/ml E. coli tRNA,
ing gel (Lu et al., 1994).and 0.5 units/ml RNasin. All the proteins used for binding
were cleaved from the GST fusion proteins using factor
Transfection and S1 analysisXa. The protein–RNA complexes were resolved from free
RNA by nondenaturing polyacrylamide gel electrophore- Transfection of 293 cells was carried out as described
sis at 47. For the U6 snRNA and dsRNA binding assays, previously (Alonso-Caplen et al., 1992). The 5*-end-la-
6 and 10% gels were used, respectively. The gels were beled single-stranded probes were prepared, and S1
run at 150 V for 3 hr using 0.045 M Tris–borate, 0.001 analysis was carried out as described previously
M EDTA as running buffer. For poly(A) binding assays, (Alonso-Caplen et al., 1992; Lu et al., 1994; Qian et al.,
a 4% gel and a running buffer of 43 mM Tris–HCl, pH 1994).
8.0, 50 mM KCl were used. The gels were run at a con-
stant current of 20 mA for 16 hr with buffer recirculation. RESULTS
The NS1 protein of influenza B virus binds to the
Chemical modification/interference analysis same RNA targets as the NS1 protein
of influenza A virusChemical modification/interference analysis was car-
ried out as described previously (Qiu et al., 1995), except The NS1 protein of influenza A virus (NS1A protein)
that the U6 snRNA substrate (3*-32P-labeled) was treated binds to three RNA targets: U6 snRNA, dsRNA, and
with anhydrous 3 M NaCl/hydrazine (for C @ U modifica- poly(A) (Qiu and Krug, 1994; Lu et al., 1995; Qiu et
tion) or with 50% hydrazine/50% H2O (for U modification) al., 1995). To determine whether the NS1 protein of
as described by Peattie (1979). influenza B virus (NS1B protein) has similar RNA-bind-
ing activities, purified NS1B protein (cleaved from a
GST – NS1B fusion protein) was incubated with each ofIn vitro translation
these RNA targets, and the formation of RNA – protein
Nuclease-treated rabbit reticulocyte extracts were pro- complexes was assayed by native gel electrophoresis.
grammed with luciferase mRNA using the TNT coupled Figure 1 shows the results obtained with the U6 snRNA
Transcription/Translation system (Promega). The reac- target. Increasing concentrations of the NS1B protein
tion mixtures contained [35S]methionine, an amino acid shifted increasing amounts of U6 snRNA into protein –
mixture (minus methionine), Sp6 RNA polymerase, and RNA complexes that migrated with lower mobilities
DNA encoding luciferase mRNA in a final volume of 10 than the free U6 snRNA during gel electrophoresis (Fig.
ml, as previously described (Lu et al., 1995). 1A). As shown previously (Qiu et al., 1995), the GST
protein alone does not form a complex with U6 snRNA
(data not shown). The protein – U6 snRNA complexesGlutathione Sepharose bead affinity selection
formed with the higher concentration (400 nM) of the
GST – NS1B protein had a lower mobility than the com-A purified fusion protein, GST fused to a NS1B se-
quence (2 mg), was combined with 5 ml of in vitro trans- plexes formed with lower concentrations of the GST –
NS1B protein. The same phenomenon was observedlated 35S-labeled, full-length NS1B protein, 20 ml glutathi-
one Sepharose 4B beads (Pharmacia), and 0.4 ml Ipp150 with the NS1A protein (Qiu et al., 1995). The NS1B
protein titration curve is similar to that previouslybuffer (10 mM Tris–HCl, pH 8.0, 0.15 mM NaCl, and 0.1%
Nonidet P-40) in a 1.5-ml Eppendorf tube. The tubes were obtained with the NS1A protein (Qiu et al., 1995). In
fact, a chemical modification/interference experimentrotated at 47 for 90 min. After the beads were washed
extensively, the labeled bound protein was eluted as showed that the NS1B protein binds to the same stem-
bulge structure in U6 snRNA as the NS1A protein (Qiudescribed previously (Nemeroff et al., 1995). The re-
sulting eluate was analyzed by electrophoresis on a 14% et al., 1995) (Figs. 1B and 1C.).
The NS1B protein also effectively formed complexesSDS–PAGE gel.
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FIG. 1. The NS1B protein binds to the same stem-bulge in U6 snRNA as does the NS1A protein. (A) RNA-binding assay. 32P-labeled U6 snRNA
(10,000 cpm, 1 nM) was mixed with the indicated concentrations of the NS1B protein under standard RNA-binding conditions as described under
Materials and Methods (lanes 2 –4). The protein–RNA complexes were separated from free RNA by nondenaturing gel electrophoresis. Lane 1, U6
snRNA alone. (B) Chemical modification/interference assay. U6 snRNA (3* 32P-labeled) was treated as described under Materials and Methods to
modify either its U residues or its C residues (C @ U). The modified U6 snRNA was incubated with the NS1B protein, the U6 snRNA–NS1B protein
complexes were isolated by nondenaturing gel electrophoresis, and the U6 snRNA was phenol extracted. This constituted the bound, or B, U6
snRNA. The U6 snRNA not bound to the NS1B protein constituted the free, or F, U6 snRNA. The F and B U6 snRNAs were cleaved with aniline,
and the resulting products were resolved by denaturing gel electrophoresis. Strong interference was observed in two regions (I and II). (C) Comparison
of the U6 snRNA nucleotides protected by the NS1B protein (—h, pyrimidines protected) and by the NS1A protein (—l, purines protected).
with dsRNA (Fig. 2A). The dsRNA used in this experiment snRNA or dsRNA (compare lanes 2 and 5 of Fig. 2B to
Figs. 1A and 2A). The specificity of the binding to poly(A)was 55 bp long and was generated by annealing the
sense and antisense transcripts of the polylinker of the was established by a competition experiment. An excess
amount of unlabeled poly(A) eliminated complex forma-pGEM1 plasmid. Again, the NS1B protein titration curve
is similar to that obtained with the NS1A protein (Lu et tion (Fig. 2B, lanes 3 and 6), whereas the same amount
of unlabeled poly(C) had no effect on complex formational., 1995). Finally, the NS1B protein formed complexes
with poly(A) (Fig. 2B). Both the NS1B and NS1A proteins (lanes 4 and 7). The NS1A and NS1B proteins behaved
similarly in this competition experiment.were less efficient in binding poly(A) than in binding U6
FIG. 2. The NS1B protein, like the NS1A protein, binds to two other RNA targets, dsRNA and poly(A). (A) 32P-labeled pGEM1 dsRNA (10,000 cpm,
1 nM) was incubated with increasing concentrations of the NS1B protein (lanes 2–5). Lane 1, pGEM1 dsRNA alone. ds, double-stranded RNA; ss,
unannealed single-stranded RNAs. (B) 32P-labeled poly(A) (10,000cpm, 0.25 nM) was mixed with 800 nM NS1B protein (lanes 2–4) or 800 nM NS1A
protein (lanes 5–7) in the absence of a competitor RNA (lanes 2 and 5) or in the presence of 1 mg unlabeled poly(A) (lanes 3 and 6) or poly(C)
(lanes 4 and 7). Lane 1, poly(A) alone.
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the NS1A protein binds to its RNA targets in the form of
a dimer (Nemeroff et al., 1995). The NS1A (1–73) polypep-
tide retains the dimerization activity of the full-length pro-
tein (Qian et al., 1995). To determine whether the NS1
protein of influenza B virus also interacted with itself via
its RNA-binding domain, we carried out the glutathione
selection assay depicted in Fig. 4A. GST fusion proteins
containing various lengths of the amino terminus of the
NS1B protein were bound to glutathione Sepharose
beads, and the ability of an 35S-labeled full-length, nonfu-
sion NS1B protein to complex with the bound GST–NS1B
sequence was determined (Fig. 4B). The two amino-ter-
minal polypeptides, NS1B (1–103) and NS1B (1–93),
FIG. 3. An amino-terminal polypeptide fragment of the NS1B protein which retained all the RNA-binding activities of the full-possesses the specific RNA-binding activities of the full-length protein.
length NS1B protein, also retained all the activity for com-Purified GST fusion proteins (200 nM) containing either the entirety of
plexing with the full-length NS1B protein (Fig. 4B, lanesthe NS1B protein (lane 4) or various lengths (78 or 93 amino acids) of
the amino-terminus fragment of the NS1B protein (lanes 2 and 3), after 2–4). In contrast, the two amino-terminal peptides that
cleavage with factor Xa, were mixed with 32P-labeled U6 snRNA (A) or lacked RNA-binding activities, NS1B (1–78) and NS1B
pGEM1 dsRNA (B) under standard RNA-binding conditions. The mix- (1–68), possessed little or no activity for complexing withtures were subjected to nondenaturing gel electrophoresis. Lane 1, U6
the full-length NS1B protein (lanes 5 and 6). Conse-snRNA (A) or dsRNA (B) alone.
quently, the RNA-binding domain was both necessary
Like its NS1A counterpart, a polypeptide comprising
the amino terminus of the NS1B protein possesses
the RNA-binding and dimerization activities
of the full-length protein
The RNA-binding domain of the NS1A protein is lo-
cated near its N-terminal end (Qian et al., 1994), and a
polypeptide comprising the amino-terminal 73 amino
acids possesses all the RNA-binding activities of the full-
length protein (Qian et al., 1995). To determine whether
an amino-terminal fragment of the NS1B protein also
constituted its RNA-binding domain, several amino-termi-
nal fragments of the NS1B protein were tested for their
abilities to bind U6 snRNA and dsRNA (Fig. 3). The frag-
ment containing the 78 amino-terminal amino acids of the
NS1B protein was inactive in binding either U6 snRNA or
dsRNA (lane 2, Figs. 3A and 3B). In contrast, the polypep-
tide containing the 93 amino-terminal amino acids of the
NS1B protein bound both U6 snRNA and dsRNA as effi-
ciently as the full-length protein (compare lanes 3 and
4). Consequently, the 93-amino-acid, amino-terminal
polypeptide of the NS1B protein (NS1B (1–93)) has the
same RNA-binding activities as the 73-amino-acid,
amino-terminal polypeptide of the NS1A protein (NS1A
FIG. 4. The NS1B protein interacts with itself in vitro via its RNA-(1–73)) (Qian et al., 1995). The binding abilities of two
binding domain. (A) Schematic diagram of the glutathione Sepharoseother amino-terminal fragments of the NS1B protein were
selection assay. (B) Binding of 35S-labeled full-length NS1B protein to
also determined: NS1B (1–103) was fully active, whereas purified GST fusion protein containing either the entirety of the NS1B
NS1B (1–68) had no detectable binding ability (data not protein (lane 2) or various lengths (68, 78, 93, or 103 amino acids) of
the amino terminus of the NS1B protein (lanes 3–6). Five microlitersshown).
of the 35S-labeled, full-length NS1B protein was incubated with 20 mlThe full-length NS1 protein of influenza A virus exists
of glutathione Sepharose 4B beads and 2 mg of the GST fusion proteinas a dimer in vitro both in the absence of its RNA target
containing the indicated NS1B sequence. Lane 1, GST protein with no
and when it is bound to U6 snRNA. Mutational analysis NS1B sequences. The 35S-labeled, full-length NS1B protein that was
indicated that the RNA-binding and dimerization domains bound to the beads was eluted and analyzed by electrophoresis on a
14% SDS–PAGE gel. Protein molecular weight markers are indicated.of the protein are coincident, strongly suggesting that
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(1–103), inhibited pre-mRNA splicing (lane 3), whereas
an amino-terminal fragment that lacked U6 snRNA-bind-
ing activity, NS1B (1–78), did not inhibit pre-mRNA splic-
ing (lane 2).
The addition of dsRNA to reticulocyte extracts acti-
vates the endogenous PKR kinase, thereby causing an
inhibition of translation (Fig. 5B, compare lanes 1 and 2)
(reviewed in Samuel, 1993). It was shown previously that
the NS1A protein, by binding to dsRNA, blocks the activa-
tion of the PKR kinase and the resulting inhibition of
translation in vitro (Lu et al., 1995). The NS1B protein
also blocked the inhibition of translation (lane 6), indicat-
ing that PKR activation by the added dsRNA was blocked.
The block of translation inhibition correlated with dsRNA-
binding activity: two amino-terminal fragments that pos-
sessed dsRNA-binding activity, NS1B (1–93) and NS1B
(1–103), blocked the inhibition of translation (Fig. 5B,
lanes 4 and 5), whereas an amino-terminal fragment that
lacked dsRNA-binding activity, NS1B (1–78), did not
block the inhibition of translation (lane 3).
FIG. 5. The NS1B protein and its amino-terminal fragment inhibit
The activities of the NS1A and NS1B proteins assplicing and block PKR activation in vitro. (A) Splicing. 32P-labeled globin
pre-mRNA was incubated for 2 hr at 307 with 10 ml HeLa cell nuclear inhibitors of pre-mRNA splicing and the nuclear
extract under splicing conditions in the absence (0) (lane 1) or the export of mRNA in vivo
presence of 1.0 mM of the indicated NS1B sequence (lanes 2–4). The
RNA products were analyzed by gel electrophoresis. US, unspliced The above results indicate that the NS1A and NS1B
globin pre-mRNA; S, spliced globin mRNA. (B) PKR activation. Reovirus proteins possess RNA-binding domains with similar ac-
dsRNA (1 mg/ml) was incubated with 200 nM of the indicated NS1B
tivities. The NS1A protein possesses a second importantsequence for 10 min at room temperature (lanes 3–6). As a control,
domain, the effector domain, that is required for its twono protein was added to the reovirus dsRNA (lane 2). The subsequent
translation reaction was carried out as described under Materials and measurable in vivo activities, the inhibition of the nuclear
Methods. The amount of protein synthesized was determined by gel export of poly(A)-containing mRNAs and the inhibition of
electrophoresis on a 14% SDS –PAGE gel followed by fluorography. pre-mRNA splicing (Lu et al., 1994; Qian et al., 1994; Qiu
Lane 1, no reovirus dsRNA was added to the reticulocyte extract.
and Krug, 1994). To determine whether the NS1B protein
possesses an effector domain like that of the NS1A pro-
tein, 293 cells were transfected with two plasmids: oneand sufficient for complexing with the full-length NS1B
specifying either the NS1A or the NS1B protein and oneprotein. Gel filtration established that, as is the case for
specifying either a globin minigene pre-mRNA to assaythe NS1A protein (Nemeroff et al., 1995; Qian et al., 1995),
splicing (Fig. 6A) or a spliced globin mRNA to assaythe NS1B protein complex is in the form of a dimer (data
nuclear export of mRNA (Fig. 6B). The NS1A and NS1Bnot shown). Formation of NS1A–NS1B heterodimers was
proteins had very different effects on globin pre-mRNAnot detected (data not shown).
splicing in vivo (Fig. 6A). In the presence of the NS1B
protein efficient splicing of the globin pre-mRNA oc-The NS1B protein and its amino-terminal fragment
curred: the ratio of unspliced to spliced globin mRNAinhibit pre-mRNA splicing and block the
was approximately 1:7 (Fig. 6A, lane 2). This is the sameactivation of the PKR kinase in vitro
extent of splicing that occurred in the absence of the
NS1B protein (Fig. 6A, lane 1). In contrast, in the presenceThe binding of the NS1A protein to U6 snRNA mole-
cules present in nuclear extracts causes the inhibition of the NS1A protein splicing of the globin pre-mRNA was
strongly inhibited: the ratio of unspliced to spliced globinof pre-mRNA splicing catalyzed by these extracts in vitro
(Lu et al., 1995; Qiu et al., 1995). As shown in Fig. 5A, mRNA was reversed, to a ratio of approximately 4:1 (Fig.
6A, lane 3), in confirmation of previous results (Lu et al.,the NS1B protein exhibited the same inhibitory activity.
Thus, the addition of the NS1B protein (1.0 mM) caused 1994). The NS1A and NS1B proteins also had very differ-
ent effects on the nuclear export of spliced globin mRNAinhibition of the splicing of a globin pre-mRNA (compare
lanes 1 and 4). Splicing inhibition correlated with U6 (Fig. 6B). In the presence of the NS1B protein the majority
(70%) of the spliced globin mRNA was transported to thesnRNA-binding activity: an amino-terminal fragment of
NS1B that possessed U6 snRNA-binding activity, NS1B cytoplasm (Fig. 6B, lanes 3 and 4), the same extent of
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into 293 cells, the splicing of a globin pre-mRNA was not
inhibited (Fig. 7B, compare lanes 1 and 2), nor was the
nuclear export of globin spliced mRNA inhibited (data
not shown). The full-length NS1A protein used as a con-
trol for this experiment is encoded by the A/Duck/Alberta/
60/76 NS1 gene (Duck NS1A), which is 100% homologous
with the A/Turkey/Oregon/71 NS1 gene except for the
absence of the 10-nucleotide deletion that caused the
truncation of the Turkey NS1A protein (Norton et al.,
1987). The Duck NS1A protein effectively inhibited globin
pre-mRNA splicing in vivo (Fig. 7B, lane 3), as well as
the nuclear export of globin spliced mRNA (data not
shown). This indicates that the Duck NS1A protein, which
FIG. 6. The NS1A, but not the NS1B, protein inhibits pre-mRNA splic- has a sequence that significantly diverges (80% similarity,
ing and the nuclear export of poly(A)-containing mRNA in vivo. (A) 68% identity) from that of the NS1 protein of A/Udorn/
Splicing in vivo. 293 cells were cotransfected with 5 mg of a pBC12 72 (Baez et al., 1981; Ludwig et al., 1991), possesses a
plasmid encoding globin pre-mRNA and 10 mg of a pBC12 plasmid
functional effector domain.encoding no protein (control, lane 1), the NS1B protein (lane 2), or the
NS1A protein (lane 3). At 40 hr posttransfection, the cells were har-
vested. Total RNA was extracted and subjected to S1 analysis using DISCUSSION
a 5*-end-labeled, single-stranded DNA probe specific for globin pre-
mRNA and spliced mRNA (Lu et al., 1994). The protected fragments Previous studies have shown both similarities and dif-
were resolved by denaturing gel electrophoresis, as shown. US, un-
ferences between the gene products of influenza A vi-spliced; S, spliced globin mRNAs. (B) Nuclear export of poly(A)-con-
ruses and those of influenza B viruses (reviewed in Lamb,taining mRNA. The pBC12 plasmid (10 mg) encoding no protein (lanes
1989). Consistent with this pattern, the present study1 and 2), the NS1B protein (lanes 3 and 4), or the NS1A protein (lanes
5 and 6) was cotransfected with 5 mg of a pBC12 plasmid encoding demonstrates that the NS1 proteins of these two influ-
spliced globin mRNA. At 40 hr posttransfection, the cells were fraction- enza virus types exhibit both similarities and differences.
ated into nuclei and cytoplasm. Cell equivalent amounts of nuclear (N)
One of the two functional domains of the NS1A protein,and cytoplasmic (C) RNAs, namely, 0.5 and 5 mg, respectively, were
the RNA-binding domain, is preserved in the NS1B pro-extracted and subjected to S1 analysis.
tein, even though there is little or no sequence homology
between the two proteins (Briedis and Lamb, 1982). The
transport that occurred in the absence of the NS1B pro-
tein (lanes 1 and 2). In contrast, in the presence of the
NS1A protein, most (95%) of the spliced globin mRNA
was retained in the nucleus (lanes 5 and 6), in confirma-
tion of previous results (Alonso-Caplen et al., 1992; Qian
et al., 1994). We verified that, as reported previously (Nor-
ton et al., 1987), the NS1B protein, like the NS1A protein,
was localized in the nucleus and that similar amounts of
the NS1A and NS1B proteins were synthesized in the
transfected cells (data not shown).
These results indicate that the NS1B protein lacks an
effector domain that functions like the NS1A protein ef-
fector domain in vivo. Consequently, the NS1B protein
would be expected to behave like the NS1 protein of
FIG. 7. The truncated NS1 protein of influenza virus A/Turkey/Oregon/a naturally occurring influenza A virus strain, A/Turkey/
71 (Turkey NS1) inhibits splicing in vitro but not in vivo. (A) In vitro. 32P-Oregon/71, which is only 125 amino acids long (Norton
labeled globin pre-mRNA was incubated for 2 hr at 307 with HeLa cellet al., 1987). This NS1A protein contains the amino half
nuclear extract under splicing conditions in the absence (control) (lane
of the molecule where the RNA-binding domain is lo- 1) or presence (lane 2) of 1.5 mM of the Turkey NS1 protein. The
cated, but lacks the carboxyl region where the effector RNA products were analyzed by gel electrophoresis. US, unspliced; S,
spliced. (B) In vivo. 293 cells were cotransfected with 5 mg of a pBC12domain normally located. This truncated NS1A (Turkey
plasmid encoding globin pre-mRNA and 10 mg of a pBC12 plasmidNS1A) protein binds to the same three RNA targets as
encoding no protein (control, lane 1), the Turkey NS1 protein (lane 2),the full-length NS1A and NS1B proteins (data not shown),
or the Duck NS1 protein (lane 3). At 40 hr posttransfection, the cells
and as a result of its binding to U6 snRNA inhibits pre- were harvested and the extracted RNAs were subjected to S1 analysis.
mRNA splicing in vitro (Fig. 7A). However, when the plas- The protected fragments were resolved by gel electrophoresis, as
shown. US, unspliced; S, spliced globin mRNA.mid encoding the Turkey NS1A protein was transfected
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NS1B protein specifically binds to the same RNA targets these two types of influenza viruses. These conclusions
raise several interrelated questions.as the NS1A protein, namely, poly(A), a stem-bulge in U6
First, why would the RNA-binding domain of the NS1snRNA, and dsRNA (Qiu and Krug, 1994; Lu et al., 1995;
protein be preserved in all influenza virus A and B virusesQiu et al., 1995; present study). For both the NS1A and
if the binding to two of its targets, poly(A) and U6 snRNA,NS1B proteins, the binding to U6 snRNA causes an inhi-
serves no apparent purpose in vivo when the proteinbition of pre-mRNA splicing in vitro, and the binding to
lacks a functional effector domain? The most plausibledsRNA blocks the activation of the PKR kinase in vitro
explanation is that the in vivo function mediated by the(Lu et al., 1994, 1995; present study). As is the case
binding of the NS1 protein to dsRNA, the third RNA target,with the NS1A protein (Qian et al., 1995), a polypeptide
is absolutely required for virus replication. Influenza viruscontaining an amino-terminal sequence of the NS1B pro-
makes large amounts of both negative-strand (i.e., virion-tein possesses all the RNA-binding activity of the full-
sense) and positive-strand viral RNAs during infection,length protein and exists in the form of a dimer. Structural
and as a consequence viral dsRNAs are formed thatstudies, using both circular dichroism (CD) and nuclear
are capable of activating the cellular PKR kinase (Katze,magnetic resonance, indicate that the amino-terminal
1992). This would cause an inhibition of the translationpolypeptide of the NS1A protein is largely a-helical (Qian
of both viral and cellular mRNAs. To block the activationet al., 1995); and CD analysis indicates that the amino-
of the PKR kinase, influenza virus apparently mounts aterminal polypeptide of the NS1B protein shares this
two-pronged attack. It has been shown that the virusproperty (unpublished data). Thus, though the RNA-bind-
activates a 58-kDa protein that inhibits the phosphoryla-ing domains of the NS1A and NS1B proteins have little
tion of the a subunit of eIF2 by the PKR kinase (Lee etor no sequence homology (Briedis and Lamb, 1982), they
al., 1990; 1992). In addition, the viral NS1 protein wouldmost likely share a structural homology. The attainment
bind to and sequester dsRNA, thereby prevent the activa-of this structural homology required amino acid se-
tion of the PKR kinase (Lu et al., 1995). It can be postu-quences of different lengths: the minimum length of the
lated that this in vivo function of the NS1 protein doesamino-terminal NS1A polypeptide that possessed RNA-
not require its effector domain, unlike the in vivo functionsbinding activity was 73 amino acids, whereas the corre-
of this protein in pre-mRNA splicing and in the nuclearsponding NS1B polypeptide was 93 amino acids.
export of poly(A)-containing mRNA (Qian et al., 1994; LuIn contrast to the preservation of the RNA-binding do-
et al., 1995). Clearly, an important goal will be to deter-
main, the second major functional domain in the NS1A
mine whether the effector domain of the NS1 protein is
protein, the effector domain, was most likely not pre-
required for its ability to block the activation of the PKR
served in the NS1B protein. The effector domain of the
kinase in vivo. Efficient blocking of PKR kinase activation
NS1A protein, which is located in the carboxyl half of the assumes even more importance during influenza virus
protein, is required for two of the in vivo activities of the infection of its vertebrate host, where virus infection in-
NS1A protein, the inhibition of the nuclear export of duces the synthesis of interferon that in turn induces the
mRNA and the inhibition of pre-mRNA splicing (Qian et synthesis of increased amounts of PKR kinase (reviewed
al., 1994; Lu et al., 1995). As shown here, the NS1B pro- in Katze, 1992; Rhoads, 1993; Samuel, 1993). According
tein lacks these in vivo activities. In cells transfected to this hypothesis, the essential function of the NS1 pro-
with the NS1B gene neither pre-mRNA splicing nor the tein for all influenza virus A and B viruses would be to
nuclear export of mRNA was inhibited. Like the NS1B protect against the activation of the PKR kinase and
protein, the NS1 protein of a naturally occurring influenza hence against the resulting inhibition of translation that
virus A strain that contains a deletion of its effector do- would block virus replication.
main region (Norton et al., 1987) has the RNA-binding Second, we have shown that a functional effector do-
activity of the full-length NS1A protein, but fails to inhibit main is present in two full-length NS1A proteins that
pre-mRNA splicing and the nuclear export of poly(A)- exhibit one of the widest divergences in NS1 sequence
containing mRNA in vivo. These results strongly suggest among influenza A viruses, those encoded by the A/
that the full-length NS1B protein lacks an effector domain Udorn/72 and A/Duck/Alberta/60/76 viruses. We can con-
that functions like that of the full-length NS1A protein. clude that a functional effector domain is most likely
The conservation of the RNA-binding domain of the preserved in all full-length NS1A proteins. Why is this
NS1 protein among influenza A and B viruses strongly effector domain preserved in all these NS1A proteins, in
suggests that this domain, which binds three RNA tar- light of the demonstration that an effector domain like
gets, poly(A), U6 snRNA, and dsRNA, is required for the that of the NS1A protein is not required for the replication
replication of these two types of influenza viruses. In of influenza B viruses nor for the replication of at least
contrast, the lack of conservation of the effector domain one influenza A virus? It has been proposed that, as a
among influenza virus A and B viruses argues that this consequence of the presence of a functional effector
domain, NS1A proteins would be able to serve severaldomain is not absolutely required for the replication of
AID VY 8076 / 6a1d$$$101 08-02-96 12:00:39 viras AP: Virology
49CONSERVATION OF VIRAL NS1 PROTEIN
and Influenza’’ (E. D. Kilbourne, Ed.), pp. 1–14. Academic Press, Newadditional functions in infected cells (Lu et al., 1994; Qiu
York.and Krug, 1994). Because of their ability to inhibit pre-
Fortes, P., Beloso, A., and Ortin, J. (1994). Influenza virus NS1 protein
mRNA splicing and the nuclear export of poly(A)-con- inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic
taining mRNA, these NS1A proteins would be able to transport. EMBO J. 13, 704–712.
Hatada, E., and Futada, R. (1992). Binding of influenza A virus NS1sequester cellular pre-mRNAs and mRNAs in the nu-
protein to dsRNA in vitro. J. Gen. Virol. 73, 3325–3329.cleus. Consequently, more of these cellular capped
Horvath, C. M., Williams, M. A., and Lamb, R. A. (1990). EukaryoticRNAs would be accessible to the viral cap-dependent
coupled translation of tandem cistrons: Identification of the influenza
endonuclease in the nucleus for the production of the B virus BM2 polypeptide. EMBO J. 9, 2639–2647.
capped RNA primers that are needed for viral mRNA Katze, M. G. (1992). The war against the interferon-induced dsRNA
activated protein kinase: can virus win? J. Interferon Res. 12, 241–synthesis (reviewed in Krug et al., 1989). This would also
248.explain the observed degradation of cellular pre-mRNAs
Katze, M. G., Detjen, B. M., Safer, B., and Krug, R. M. (1986). Transla-and mRNAs in the nucleus of infected cells (Katze and
tional control by influenza virus: suppression of the kinase that phos-
Krug, 1984). In addition, these NS1A proteins would be phorylates the alpha subunit of initiation factor eIF-2 and selective
capable of regulating the early-to-late switch in viral pro- translation of influenza viral mRNAs. Mol. Cell. Biol. 6, 1741–1750.
Katze, M. G., and Krug, R. M. (1984). Metabolism and expression oftein synthesis by retaining the late viral mRNAs in the
RNA polymerase II transcripts in influenza virus infected cells. Mol.nucleus until the appropriate time for their expression.
Cell. Biol. 4, 2198–2206.Is there some reason that almost all influenza A viruses
Katze, M. G., Tomita, J., Black. T., Krug, R. M., Safer, B., and Hovanessian,
retain the ability to carry out these functions, whereas A. (1988). Influenza virus regulates protein synthesis during infection
influenza B viruses do not? by repressing autophosphorylation and activity of the cellular 68,000-
Mr protein kinase. J. Virol. 62, 3710–3717.Finally, the NS1 proteins of almost all influenza B vi-
Kilbourne, E. D. (1975). The influenza viruses and influenza—An intro-ruses possess a large carboxyl region that not functions
duction. In ‘‘The Influenza Viruses and Influenza’’ (E. D. Kilbourne,like the effector domain of NS1A protein. What is the
Ed.), pp. 1–14. Academic Press, New York.
function of the carboxyl region of these NS1B proteins, Krug, R. M. (1989). Expression and replication of the influenza virus
particularly in light of the existence of a laboratory B virus genome. In ‘‘The Influenza Viruses’’ (R. M. Krug, Ed.), pp. 89–152.
Plenum, New York.variant with a truncated NS1 protein lacking the carboxyl
Lamb, R. A. (1983). The influenza virus RNA segments and their en-region (Norton et al., 1987)? The answers to these ques-
coded proteins. ‘‘Genetics of Influenza Viruses’’ (P. Palese and D. W.tions should provide insights into the different biological
Kingsbury, Eds.), pp. 26–69. Springer-Verlag, Vienna.
properties of influenza A and B viruses. Lamb, R. A. (1989). Genes and proteins of the influenza viruses. In ‘‘The
influenza viruses’’ (R. M. Krug, Ed.), pp. 1–87. Plenum, New York.
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